vs
FIRST FINANCIAL BANCORP（FFBC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
FIRST FINANCIAL BANCORP的季度营收约是Orthofix Medical Inc.的1.2倍（$271.5M vs $219.9M），FIRST FINANCIAL BANCORP净利率更高（27.4% vs -1.0%，领先28.4%），过去两年FIRST FINANCIAL BANCORP的营收复合增速更高（12.4% vs 8.0%）
第一金融银行集团是总部位于美国俄亥俄州辛辛那提的区域性银行，运营中心设于辛辛那提北郊斯普林代尔及印第安纳州格林斯堡。该行成立于1863年，拥有美国第六悠久的国家银行牌照，在俄亥俄、印第安纳、肯塔基、伊利诺伊四州共设有131个营业网点，2009年9月曾在政府协助下收购欧文金融公司及其子公司。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
FFBC vs OFIX — 直观对比
营收规模更大
FFBC
是对方的1.2倍
$219.9M
净利率更高
FFBC
高出28.4%
-1.0%
两年增速更快
FFBC
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $271.5M | $219.9M |
| 净利润 | $74.4M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 27.4% | -1.0% |
| 营收同比 | — | 2.0% |
| 净利润同比 | 19.3% | 92.4% |
| 每股收益（稀释后） | $0.71 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FFBCOFIX
| Q1 26 | $271.5M | — | ||
| Q4 25 | $238.8M | $219.9M | ||
| Q3 25 | $234.0M | $205.6M | ||
| Q2 25 | $226.3M | $203.1M | ||
| Q1 25 | $200.4M | $193.6M | ||
| Q4 24 | $224.3M | $215.7M | ||
| Q3 24 | $201.3M | $196.6M | ||
| Q2 24 | $214.8M | $198.6M |
净利润FFBCOFIX
| Q1 26 | $74.4M | — | ||
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $71.9M | $-22.8M | ||
| Q2 25 | $70.0M | $-14.1M | ||
| Q1 25 | $51.3M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $52.5M | $-27.4M | ||
| Q2 24 | $60.8M | $-33.4M |
毛利率FFBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率FFBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | 38.7% | -8.3% | ||
| Q2 25 | 38.8% | -7.9% | ||
| Q1 25 | 31.7% | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | 32.2% | -9.6% | ||
| Q2 24 | 34.8% | -12.5% |
净利率FFBCOFIX
| Q1 26 | 27.4% | — | ||
| Q4 25 | — | -1.0% | ||
| Q3 25 | 30.7% | -11.1% | ||
| Q2 25 | 30.9% | -6.9% | ||
| Q1 25 | 25.6% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 26.1% | -13.9% | ||
| Q2 24 | 28.3% | -16.8% |
每股收益（稀释后）FFBCOFIX
| Q1 26 | $0.71 | — | ||
| Q4 25 | $0.64 | $-0.05 | ||
| Q3 25 | $0.75 | $-0.57 | ||
| Q2 25 | $0.73 | $-0.36 | ||
| Q1 25 | $0.54 | $-1.35 | ||
| Q4 24 | $0.68 | $-0.76 | ||
| Q3 24 | $0.55 | $-0.71 | ||
| Q2 24 | $0.64 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | $13.1M | — |
| 股东权益账面价值 | $2.9B | $450.0M |
| 总资产 | $22.5B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资FFBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M |
总债务FFBCOFIX
| Q1 26 | $13.1M | — | ||
| Q4 25 | $514.1M | — | ||
| Q3 25 | $221.8M | $157.2M | ||
| Q2 25 | $345.0M | $157.0M | ||
| Q1 25 | $345.9M | $156.9M | ||
| Q4 24 | $347.5M | $157.0M | ||
| Q3 24 | $344.1M | $118.5M | ||
| Q2 24 | $338.6M | $118.0M |
股东权益FFBCOFIX
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.8B | $450.0M | ||
| Q3 25 | $2.6B | $442.5M | ||
| Q2 25 | $2.6B | $458.3M | ||
| Q1 25 | $2.5B | $458.3M | ||
| Q4 24 | $2.4B | $503.1M | ||
| Q3 24 | $2.5B | $525.9M | ||
| Q2 24 | $2.3B | $546.0M |
总资产FFBCOFIX
| Q1 26 | $22.5B | — | ||
| Q4 25 | $21.1B | $850.6M | ||
| Q3 25 | $18.6B | $832.6M | ||
| Q2 25 | $18.6B | $837.2M | ||
| Q1 25 | $18.5B | $823.1M | ||
| Q4 24 | $18.6B | $893.3M | ||
| Q3 24 | $18.1B | $867.9M | ||
| Q2 24 | $18.2B | $882.0M |
负债/权益比FFBCOFIX
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.08× | 0.36× | ||
| Q2 25 | 0.13× | 0.34× | ||
| Q1 25 | 0.14× | 0.34× | ||
| Q4 24 | 0.14× | 0.31× | ||
| Q3 24 | 0.14× | 0.23× | ||
| Q2 24 | 0.15× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流FFBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $337.9M | $27.7M | ||
| Q3 25 | $89.8M | $12.4M | ||
| Q2 25 | $69.8M | $11.6M | ||
| Q1 25 | $56.1M | $-18.4M | ||
| Q4 24 | $262.2M | $23.7M | ||
| Q3 24 | $88.1M | $11.7M | ||
| Q2 24 | $68.1M | $9.0M |
自由现金流FFBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $317.1M | $16.8M | ||
| Q3 25 | $85.8M | $2.5M | ||
| Q2 25 | $64.8M | $4.5M | ||
| Q1 25 | $52.4M | $-25.1M | ||
| Q4 24 | $241.1M | $15.2M | ||
| Q3 24 | $84.4M | $6.3M | ||
| Q2 24 | $64.8M | $-360.0K |
自由现金流率FFBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 132.8% | 7.6% | ||
| Q3 25 | 36.7% | 1.2% | ||
| Q2 25 | 28.6% | 2.2% | ||
| Q1 25 | 26.1% | -13.0% | ||
| Q4 24 | 107.5% | 7.0% | ||
| Q3 24 | 42.0% | 3.2% | ||
| Q2 24 | 30.2% | -0.2% |
资本支出强度FFBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 8.7% | 4.9% | ||
| Q3 25 | 1.7% | 4.8% | ||
| Q2 25 | 2.2% | 3.5% | ||
| Q1 25 | 1.9% | 3.5% | ||
| Q4 24 | 9.4% | 4.0% | ||
| Q3 24 | 1.8% | 2.7% | ||
| Q2 24 | 1.5% | 4.7% |
现金转化率FFBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.25× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.09× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.68× | — | ||
| Q2 24 | 1.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FFBC
| Net Interest Income | $189.6M | 70% |
| Noninterest Income | $81.9M | 30% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
